Inventor, entrepreneur and educator: 22 yrs industry and academic experience in commercializing new technologies, 25 issued patents Founded businesses in Healthcare IT (Dossia), genome analysis (Intel Genomics), cardiac imaging (CardioWise); Orthopedics (OsteoVantage) and others. Academic positions at Harvard Medical School, UCLA and RPI; Corporate Management at Intel and Kodak.

Primary Investigator of Ascendant’s - Melody Dx Pioneer of new breast cancer surgery techniques Director of breast cancer program at Rockefeller Cancer Institute at UAMS President, Society of Surgical Oncology Board member of American Cancer Society, Former Board Member at The Komen Foundation.

Dr. Daily joined Ascendant Dx in January of 2011 after completing a post-doctoral position in the Department of Chemistry and Biochemistry at the University of Arkansas. Daily has been leading the research and development of MelodyDx, a tear protein-based assay for the detection of breast cancer.

Dr. Rutherford received her PhD in Biochemistry from the University of Arkansas in 2011. After completing her PhD, she served as a scientist at BiologicsMD focusing on development of a treatment for osteoporosis. As a senior scientist at Ascendant Diagnostics, Rutherford provides expertise in the expression and purification of recombinant proteins, bacterial and mammalian cell culture as well as extensive ELISA assay development.